JAZZ

#712
Jazz Pharmaceuticals plc - Ordinary Shares
234.3 2 USD
+9854.97%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
233.14
234.66
Year Range
2.37
243.32
Daily Change
+9854.97%
Monthly Change
+15.99%
6 month change
+34.49%
Year Change
+67.37%
Previous Close
2.3 5
Open
234.6 3
Low
233.1 4
High
234.6 6
Volume
365
Open full chart Full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 14.7 B
  • Employee 2 890
  • Founded 2003
  • CEO Bruce C Cozadd
  • Website www.jazzpharmaceuticals.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
1 718.64
Price to sales ratio
2.66

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

News